Kathleen M Hayden1, Sarah A Gaussoin2, Jaimie C Hunter1, JoAnn E Manson3, Bonnie C Sachs1,4,5, Aladdin H Shadyab6, Hilary A Tindle7, Yasmin Mossavar-Rahmani8, Khyobeni Mozhui9, Beverly M Snively2, Stephen R Rapp1,10, Susan M Resnick11. 1. Department of Social Sciences and Health Policy, Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC. 2. Department of Biostatistics and Data Science, Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC. 3. Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. 4. Department of Internal Medicine, Section on Geriatrics and Gerontology, Wake Forest School of Medicine, Winston-Salem, NC. 5. Department of Neurology, Wake Forest School of Medicine, Winston-Salem, NC. 6. Department of Family Medicine and Public Health, University of California San Diego School of Medicine, La Jolla, CA. 7. Geriatric Research Education and Clinical Centers (GRECC), Veterans Affairs Tennessee Valley Healthcare System, Vanderbilt University Medical Center, Nashville, TN. 8. Department of Epidemiology and Population Health, Albert Einstein College of Medicine, New York City, NY. 9. Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, TN. 10. Department of Psychiatry and Behavioral Medicine, Wake Forest School of Medicine, Winston-Salem, NC. 11. Laboratory of Behavioral Neuroscience, National Institute on Aging, Baltimore, MD.
Abstract
OBJECTIVES: Relatively few APOE ε4+ carriers survive to old age (age 80+) without cognitive impairment (CI); thus, little is known about distinguishing characteristics of resilient APOE ε4+ carriers. Herein, we describe the sociodemographic characteristics of a large sample of resilient APOE ε4+ women from the Women's Health Initiative Memory Study (WHIMS) and compare them to noncarriers and APOE ε4+ women who developed CI before age 80. METHODS: Women were recruited for clinical trials evaluating postmenopausal hormone therapy and incidence of dementia. During posttrial follow-up, cognitive status was adjudicated annually. Among 5716 women, we compared groups by APOE ε4 status using logistic regression, covarying for treatment, demographics, lifestyle, cardiovascular and physical function, well-being, and self-rated general health. RESULTS: Among 557 APOE ε4+ women, those who survived to age 80+ without CI had higher baseline self-rated general health (odds ratio [OR]: 1.02; 95% confidence interval [CI], 1.01-1.04) and cognitive scores (OR: 1.18; 95% CI, 1.12-1.25) than those who did not reach age 80 without CI. Baseline high total cholesterol and low-density lipoprotein (LDL) levels were similar across APOE ε4+ groups but were higher compared with APOE ε4- women. Among women who survived to 80+ without CI, more APOE ε4+ women had a history of high total cholesterol (P = .003) and LDL cholesterol (OR: 1.01; 95% CI, 1.00-1.01). There were no differences in hypertension, diabetes, or other vascular risk factors in APOE ε4+ women compared with noncarriers. CONCLUSIONS: Results highlight the importance of baseline cognitive function and general health for late-life cognition among ε4+ women.
OBJECTIVES: Relatively few APOE ε4+ carriers survive to old age (age 80+) without cognitive impairment (CI); thus, little is known about distinguishing characteristics of resilient APOE ε4+ carriers. Herein, we describe the sociodemographic characteristics of a large sample of resilient APOE ε4+ women from the Women's Health Initiative Memory Study (WHIMS) and compare them to noncarriers and APOE ε4+ women who developed CI before age 80. METHODS:Women were recruited for clinical trials evaluating postmenopausal hormone therapy and incidence of dementia. During posttrial follow-up, cognitive status was adjudicated annually. Among 5716 women, we compared groups by APOE ε4 status using logistic regression, covarying for treatment, demographics, lifestyle, cardiovascular and physical function, well-being, and self-rated general health. RESULTS: Among 557 APOE ε4+ women, those who survived to age 80+ without CI had higher baseline self-rated general health (odds ratio [OR]: 1.02; 95% confidence interval [CI], 1.01-1.04) and cognitive scores (OR: 1.18; 95% CI, 1.12-1.25) than those who did not reach age 80 without CI. Baseline high total cholesterol and low-density lipoprotein (LDL) levels were similar across APOE ε4+ groups but were higher compared with APOE ε4- women. Among women who survived to 80+ without CI, more APOE ε4+ women had a history of high total cholesterol (P = .003) and LDL cholesterol (OR: 1.01; 95% CI, 1.00-1.01). There were no differences in hypertension, diabetes, or other vascular risk factors in APOE ε4+ women compared with noncarriers. CONCLUSIONS: Results highlight the importance of baseline cognitive function and general health for late-life cognition among ε4+ women.
Authors: Kathleen M Hayden; Peter P Zandi; Constantine G Lyketsos; JoAnn T Tschanz; Maria C Norton; Ara S Khachaturian; Carl F Pieper; Kathleen A Welsh-Bohmer; John C S Breitner Journal: J Am Geriatr Soc Date: 2005-06 Impact factor: 5.562
Authors: Allison R Kaup; Jasmine Nettiksimmons; Tamara B Harris; Kaycee M Sink; Suzanne Satterfield; Andrea L Metti; Hilsa N Ayonayon; Kristine Yaffe Journal: JAMA Neurol Date: 2015-03 Impact factor: 18.302
Authors: A Solomon; I Kåreholt; T Ngandu; B Winblad; A Nissinen; J Tuomilehto; H Soininen; M Kivipelto Journal: Neurology Date: 2007-03-06 Impact factor: 9.910
Authors: Sally A Shumaker; Claudine Legault; Stephen R Rapp; Leon Thal; Robert B Wallace; Judith K Ockene; Susan L Hendrix; Beverly N Jones; Annlouise R Assaf; Rebecca D Jackson; Jane Morley Kotchen; Sylvia Wassertheil-Smoller; Jean Wactawski-Wende Journal: JAMA Date: 2003-05-28 Impact factor: 56.272
Authors: Madhav Thambisetty; E Jeffrey Metter; An Yang; Hillary Dolan; Christopher Marano; Alan B Zonderman; Juan C Troncoso; Yun Zhou; Dean F Wong; Luigi Ferrucci; Josephine Egan; Susan M Resnick; Richard J O'Brien Journal: JAMA Neurol Date: 2013-09-01 Impact factor: 18.302
Authors: Sally A Shumaker; Claudine Legault; Lewis Kuller; Stephen R Rapp; Leon Thal; Dorothy S Lane; Howard Fillit; Marcia L Stefanick; Susan L Hendrix; Cora E Lewis; Kamal Masaki; Laura H Coker Journal: JAMA Date: 2004-06-23 Impact factor: 56.272
Authors: Anne M Murray; Yelena Slinin; David E Tupper; Sarah L Pederson; Cynthia Davey; David T Gilbertson; Paul Drawz; Ryan Mello; Allyson Hart; Kirsten L Johansen; Scott Reule; Rebecca Rossom; David S Knopman Journal: Am J Nephrol Date: 2022-04-28 Impact factor: 4.605
Authors: Olga Lucia Pedraza; Isis Camacho; Fabio Alexander Sierra; Rubio-Gómez Cladelis; Ana Maria Salazar; Maria Camila Montalvo; Hector Daniel Morillo; Angela Lozano; Luz Dary Gutiérrez-Castañeda; Lilian Torres-Tobar; Cesar Piñeros Journal: Dement Neuropsychol Date: 2021 Oct-Dec